Cancer immunology research
IL4/IL13 inhibition via dupilumab reduces malignant T cell proliferation and promotes antitumor immunity in Sezary syndrome.
Larisa J Geskin, Alyxzandria M Gaydosik, Brigit Lapolla, Patrizia Fuschiotti
Published: 202510.1158/2326-6066.CIR-25-0677
Abstract
Patients with Sezary syndrome (SS), the aggressive leukemic variant of cutaneous T cell lymphoma (CTCL), have few therapeutic options and a poor prognosis. We previously showed that the IL4/IL13 signaling pathway impacts SS tumorigenesis. Here, we in…
Preview only. Read the full abstract at the source